Physician profile
Ross Mandeville
NPI 1205084183
$2,504.79
in general payments reported to CMS, 2019-2025
24 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2021: $103 · 2024: $246 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,161 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,160.97 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $388.02 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $346.95 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $320.10 | 2024-2025 | Ingrezza |
| Ucb, INC. | $222.91 | 2025 | Zilbrysq, Briviact |
| Janssen Biotech, INC. | $221.32 | 2025 | |
| Checkpoint Surgical, INC | $145.89 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $143.39 | 2025 | Austedo Xr |
| Integra Lifesciences Corporation | $102.94 | 2021 | |
| Grifols USA, LLC | $100.95 | 2024-2025 | Gamunex-C |
| Biogen, INC. | $65.11 | 2025 | Vumerity, Tysabri, Spinraza |
| Pfizer INC. | $50.96 | 2025 | |
| Lundbeck LLC | $48.10 | 2024-2025 | Vyepti |
| Lilly USA, LLC | $47.17 | 2024-2025 | Kisunla |
| Emd Serono, INC. | $43.22 | 2025 | |
| Amneal Pharmaceuticals LLC | $42.29 | 2025 | Crexont |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $32.15 | 2025 | Gocovri |
| Otsuka America Pharmaceutical, INC. | $30.63 | 2025 | Rexulti |
| Abbott Laboratories | $30.11 | 2024 | Infinity |
| Eisai INC. | $25.36 | 2025 | |
| Catalyst Pharmaceuticals, INC. | $23.74 | 2025 | |
| Alnylam Pharmaceuticals INC. | $23.59 | 2025 | Amvuttra |
| Tanabe Pharma America, INC. | $20.77 | 2025 | Radicava |
| Philips North America LLC | $18.49 | 2025 | Extended Holter |
| Aucta Pharmaceuticals, INC. | $10.63 | 2024 | Motpoly Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Mandeville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.